{'fraction_non_alphanumeric': 0.02040816326530612, 'fraction_numerical': 0.0, 'mean_word_length': 5.802919708029197, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Quantitative ultrasound monitoring of breast tumor response to chemotherapy by analysis of frequency-dependent attenuation and backscattered power

Conventional assessment of tumor response to anti-cancer therapy is based on measurements of tumor size (RECIST criteria). However, these measurements are typically a late indicator of tumor response (detectable after several weeks to a few months). There is currently no method to assess tumor response early in the course of therapy. In this study, quantitative ultrasound (QUS) methods were used to characterize the frequency-dependent attenuation and backscatter properties of treatment responding and non-responding tumors in breast cancer patients receiving neoadjuvant chemotherapy. In addition, we assessed the effects of attenuation correction of the power spectrum on the ability to differentiate between responding and non-responding tumors during the course of treatment.